Resecting Non–Contrast-Enhancing Tumor in Glioblastoma: Mitchel Berger, MD

​In patients with newly diagnosed glioblastoma, maximal extent of surgical resection of contrast-enhancing tumor has consistently been associated with benefits to survival. However, in a practice-changing study published recently in JAMA Oncology, a team of investigators under the leadership of Mitchel Berger, MD, found that extending resection to include non–contrast-enhancing tumor as well as contrast-enhancing tumor is associated with increased survival, regardless of tumor genetic subtype. I...
Continue reading

HSD3B1 Genotype and Prostate Cancer Outcomes: Nima Sharifi, MD

Men with metastatic castration-sensitive prostate cancer (CSPC) generally experience an initial response to androgen deprivation therapy (ADT), but with time, the cancer invariably becomes castration resistant. A new analysis of data from the phase 3 CHAARTED trial, published last week in JAMA Oncology, shows that men with low-volume metastatic CSPC who have the adrenal-permissive genotype of the HSD3B1 gene experience more rapid progression to castration-resistant disease and shorter overall su...
Continue reading

Baseline Liver Function As a Prognostic Factor in Unresectable HCC: Arndt Vogel, MD

In the phase 3 REFLECT trial, lenvatinib, an oral multikinase inhibitor, showed non-inferior survival compared with sorafenib in patients with untreated, unresectable hepatocellular carcinoma (HCC). However, the assessment of baseline liver function as a prognostic factor for patients with unresectable HCC receiving lenvatinib had not yet been investigated. In a post hoc analysis of the trial, a team of researchers led by Arndt Vogel, MD, Professor of Gastrointestinal Oncology at Hannover Medica...
Continue reading

Enhancing Treatment for Patients With GIST: Michael Heinrich, MD

​Because gastrointestinal stromal tumor (GIST) has an estimated incidence of 3,300 to 6,000 new cases per year in the United States, comprising less than 1% of all gastrointestinal tumors, the rarity of this tumor type can make it more challenging for oncologists and other members of the cancer care team to stay up to date on the latest treatments. Michael C. Heinrich, MD, lead investigator of the phase 1 NAVIGATOR trial, recently spoke with i3 Health about the FDA's approval of avapritinib (Ayv...
Continue reading

How Genetic Testing Results Impact Breast Cancer Treatment: Allison Kurian, MD, MSc

​With our ever-growing understanding of mutations that increase cancer risk and the rise of targeted treatments such as poly (ADP-ribose) polymerase (PARP) inhibitors that are indicated for specific mutations, the use of germline genetic testing for patients with breast cancer has increased significantly in recent years. How are these test results affecting patients' treatment? In a population-based cohort study published recently published in JAMA Oncology, Allison W. Kurian, MD, MSc, and colle...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.